ERBE-ELEKTROMEDIZIN
6.6.2024 08:12:27 CEST | Business Wire | Press release
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the largest single investment in the company's history and represents another important part in the global network. The building combines production, product development, logistics and administration. Erbe will now develop and produce medical technology instruments for customers all over the world at its Rangendingen site near Tübingen. With the new building, the company is expanding its capacities and is even better equipped to deal with the consequences of global crises. The building is a pioneering achievement in terms of ecological, social and economic sustainability. Among the guests on May 3 were the Chairman of the Free Democratic Party, Christian Lindner, and the Minister of Economic Affairs of Baden-Württemberg, Dr. Nicole Hoffmeister-Kraut.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603323747/en/
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
On May 3rd, Erbe opened its newest plant in Rangendingen near Tübingen. The new competence center is dedicated to the development and production of medical instruments for our customers around the world. Erbe is expanding its capacities in order to be even more robust in case of supply bottlenecks resulting from international crisis. In this manner, Erbe ensures uninterrupted business operations. This enables us to consistently deliver the highest quality to our customers worldwide.
An important aspect for ensuring continuous economic success is the concept of sustainability. For Erbe, “Made in Germany” means the future of Germany as a business location in harmony with innovative medical technology and a pioneering role for sustainable, responsible entrepreneurship.
“Erbe is a symbol of what makes our country strong,” explained Christian Lindner, Chairman of the Free Democratic Party (FDP) in his speech. He commended the location decision and emphasized the importance of supporting family businesses, stating, “They are the ones who create prosperity.”
“We have set the course for a new standard with our construction project in Rangendingen,” explains Marcus Felstead, Chief Commercial Officer.
“Because tomorrow's customers will place even more value on sustainability than we already do today. We want to meet these demands.”
Both planning and construction of the building had this as a goal. In order to realize ecological, social and economic aspects of the corporate strategy and combine them in an industrial building, Erbe relied on the use of high-quality ecological building materials for the supporting structure and the façade, the use of renewable energy technology and the implementation of numerous measures for an optimal working environment for employees.
A highlight of the building is one of the largest photovoltaic systems in the region. The 2,800 solar panels on the roof with an output of 1 MW produce 610,000 kWh of electricity per year and cover a third of the energy required for operations. This is supplemented by a combined heat and power plant powered by CO2-neutral biogas.
“We implemented the most demanding standards for energy efficiency and achieved KfW Efficiency Level 40 Plus,” explains Christian O. Erbe. “This means, that our building is more than twice as energy efficient compared to conventional structures, making it a leader in the field of sustainable industrial building.”
Up to 500 employees will be working on site. They benefit from a modern, employee-centered working environment. The company's social responsibility also includes a distinctive health concept for employees, including company medical care, health weeks and financial support for sporting activities. There are exercise islands in the building for fitness, a room for yoga, leisure activities and relaxation rooms.
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 18 international sales and service units
- 4 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- Over 1,900 employees worldwide
- Some 1,000 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tübingen
www.erbe-med.com
info@erbe-med.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603323747/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 09:00:00 CET | Press release
AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat
SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 08:50:00 CET | Press release
The agreement ensures Europe’s satellite-based augmentation continues enhancing navigation for aviation and other critical users and lowering emissions SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports mar
LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 08:30:00 CET | Press release
Key win in LTTS’ Mobility Segment across multiple vehicle technology domains L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and
SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 08:00:00 CET | Press release
Equazen® Forte represents a strategic evolution of the brand, extending its clinically researched omega-3 based cognitive support product formulation beyond children to young adults and adults through pharmacies across Poland. SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changi
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
